Carmot Therapeutics

8 February 2010

Carmot Therapeutics, Inc. and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that Sunesis has granted Carmot an exclusive license to its proprietary Fragment-Based Lead Discovery (FBLD) technology. Carmot will use the FBLD technology, called “Chemotype Evolution,” for identifying promising drug candidates in a broad range of therapeutic areas, including inflammatory, metabolic, and neurodegenerative diseases.  Sunesis retains full rights to the technology for use in its future internal discovery efforts.  Terms of the agreement were not disclosed.

“We believe that Chemotype Evolution has the potential to transform drug discovery and accelerate our efforts to identify novel drug candidates for challenging disease targets,” stated Stig K. Hansen, Ph.D. and Daniel A. Erlanson, Ph.D., co-founders of Carmot. Hansen and Erlanson were inventors of the technology while at Sunesis Pharmaceuticals and founded Carmot in 2008. Carmot has recently received grants from the National Science Foundation and the Michael J. Fox Foundation for Parkinson’s Research.

For more information about Chemotype Evolution, click here.

Contact information: info@carmot.us